Adolore BioTherapeutics Announces FDA Orphan Drug Designation for its Kv7-activating rdHSV-CA8* Therapy in the Treatment of Erythromelalgia

Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due to ...
Pharmabiz

US FDA grants Orphan Drug Designation to Adolore BioTherapeutics’ Kv7-activating rdHSV-CA8 therapy to treat erythromelalgia

US FDA grants Orphan Drug Designation to Adolore BioTherapeutics’ Kv7-activating rdHSV-CA8 therapy to treat erythromelalgia: Delray Beach, Florida Friday, January 16, 2026, 17:0 ...

Adolore Biotherapeutics, Inc.: Adolore BioTherapeutics Announces FDA Orphan Drug Designation for its Kv7-activating rdHSV-CA8* Therapy in the Treatment of Erythromelalgia

Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due to hereditary neuronal sodium ion channel mutationsAdolore's Kv7 voltage-gated po ...

NanoPass Technologies Expands Product Portfolio to Advance Intradermal Delivery

NanoPass Technologies Ltd., a global leader in intradermal delivery solutions, will officially launch MicronJet™ 800 during ...
AlphaGalileo

Microneedle Technology for Overcoming Biological Barriers: Advancing Biomacromolecular Delivery in Major Diseases

Biomacromolecules are increasingly important for treating major diseases such as tumors, infections, cardiovascular diseases, metabolic disorders, ...

PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs

Detailed price information for Pharmather Hldgs Ltd (PHRRF) from The Globe and Mail including charting and trades.